First Bank & Trust boosted its holdings in shares of Catalent Inc (NYSE:CTLT) by 54.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,764 shares of the company’s stock after acquiring an additional 1,323 shares during the period. First Bank & Trust’s holdings in Catalent were worth $155,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. 361 Capital LLC raised its position in Catalent by 18.6% during the third quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock worth $2,795,000 after acquiring an additional 10,974 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Catalent by 25.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock worth $41,773,000 after buying an additional 210,296 shares in the last quarter. Stevens Capital Management LP purchased a new stake in shares of Catalent during the third quarter worth about $2,475,000. Sei Investments Co. grew its holdings in shares of Catalent by 119.1% during the third quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock worth $3,761,000 after buying an additional 51,212 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Catalent during the second quarter worth about $23,092,000. Institutional investors own 99.37% of the company’s stock.
In related news, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by insiders.
Shares of Catalent Inc (NYSE:CTLT) traded up $0.41 during midday trading on Thursday, hitting $43.05. 716,400 shares of the stock were exchanged, compared to its average volume of 670,836. Catalent Inc has a 1-year low of $25.69 and a 1-year high of $43.42. The stock has a market capitalization of $5,665.13, a P/E ratio of 49.48, a PEG ratio of 2.71 and a beta of 1.41. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01.
Catalent (NYSE:CTLT) last released its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. During the same period in the previous year, the firm earned $0.16 earnings per share. Catalent’s revenue was up 23.0% compared to the same quarter last year. analysts expect that Catalent Inc will post 1.47 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/18/first-bank-trust-increases-holdings-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.